Shifting the paradigm

Where technology
meets Human

Volv Global generates new insight into difficult-to-diagnose diseases, powered by proprietary machine learning and real-world data.

Our proprietary machine learning methodologies serve pharmaceutical companies, reducing costs across the healthcare ecosystem and improving outcomes for people living with disease.

Portrait with turquoise and amber geometric shapes

Mapping the
patient journey

Volv Global's research shows how patients move through diagnosis, treatment and care, and where the pathway fails them.

Targeting patient
populations

Volv Global's methodology characterises and segments patient populations, giving healthcare organisations and patients clearer pathways, and pharmaceutical teams more efficient development and commercialisation.

Expanding medical knowledge

Volv Global generates new understanding of patient biomarkers, phenotypes, clinical features and endpoints, helping clinicians see how a disease presents.

Improving health-
care efficiency

Late and incorrect diagnosis carries an avoidable cost across the system, from unnecessary testing to delayed care. Volv Global's research quantifies that burden, giving pharma and payers the evidence to act on it.

Patient insights from real-world data, Volv Global

Volv Global helps you work smarter

Adding value through unprecedented insights

Volv Global uses AI and real-world data to generate knowledge about difficult-to-diagnose diseases.

Clients use these insights to strengthen clinical development strategy, deepen disease understanding, and find opportunities to develop diagnostic tools faster.

The same insights support repositioning existing drugs to extend their R&D viability, helping clients reach new markets and work smarter.

Volv Global, in numbers

Billion medical events
13.69
Billion person-years of health data
4.22
Our founders published first AI/ML papers
2009

Volv Global delivers high-value solutions at speed

Impact across the product lifecycle

inCare finding eligible patients, Volv Global

Driving innovation in rare disease & healthcare AI

AI Powered Solutions for Rare Disease and Healthcare Innovation

At Volv Global, we combine advanced AI in healthcare with real-world data (RWD) to deliver transformative solutions for rare and difficult-to-diagnose disease patients. Our proprietary methodology for machine learning in healthcare technology enables:

  • Researching how rare diseases can be recognised earlier in real-world data
  • Generating real-world evidence (RWE) to inform trial design
  • Mapping the patient journey with data-driven insights
  • Reducing time and costs in drug development and market access

By partnering with Volv Global, pharmaceutical innovators, healthcare providers, and policymakers gain the evidence to make smarter, faster decisions.

New knowledge, at speed

Cover2

Introducing inTrigue

Advanced, proprietary machine learning technology for patient-disease insights

With inTrigue, our flagship machine learning methodology, Volv Global studies difficult-to-diagnose disease at population scale, showing where patients are missed and why.

Understanding patient phenomenology, across all diseases.

Volv Global’s suite of services

Volv Global machine learning methodology for rare diseases

The human story

Improving lives with better tools and treatments

Volv Global gives pharmaceutical innovators insight into difficult-to-diagnose diseases, so they can develop effective technology and treatments.

For the patient, this can mean an earlier diagnosis, a life-changing drug, or the chance to connect with a wider community for education and support while living with a rare disease.

Every individual matters

Stay informed

Insights & Events

Go​ deeper

Case studies​